Clinical Pharmacology of Pyridostigmine and Neostigmine in Patients with Myasthenia Gravis

Overview

Journal J Neurol Neurosurg Psychiatry

Publisher BMJ Publishing Group

Specialties Neurology
Neurosurgery
Psychiatry

Date 1983 Oct 1

PMID 6644317

Citations 12

Authors

S M Aquilonius

S A Eckernas

P Hartvig

B Lindstrom

P O OSTERMAN

E Stalberg

Affiliations

Soon will be listed here.

Abstract

Determination of plasma concentration of pyridostigmine in 20 myasthenic patients on maintenance therapy revealed rather small intraindividual variations within a dose interval. The predose concentration varied considerably between different patients and up to seven fold in patients on the same daily dose. No pharmacokinetic interaction between pyridostigmine and neostigmine was found in five patients studied. In six patients the decrement in the deltoid muscle was studied in parallel with determination of the plasma concentrations following administration of pyridostigmine or neostigmine. In these patients the existence of a "bell-shaped" dose response curve is suggested with the maximal effect at a concentration of 30-60 ng/ml for pyridostigmine and 5-15 ng/ml for neostigmine.

Citing Articles

gPKPDSim: a SimBiology-based GUI application for PKPD modeling in drug development.

Hosseini I, Gajjala A, Bumbaca Yadav D, Sukumaran S, Ramanujan S, Paxson R J Pharmacokinet Pharmacodyn. 2018; 45(2):259-275.

PMID: 29302838 PMC: 5845055. DOI: 10.1007/s10928-017-9562-9.

Environmental effects of anticholinesterasic therapeutic drugs on a crustacean species, Daphnia magna.

Rocha R, Goncalves F, Marques C, Nunes B Environ Sci Pollut Res Int. 2013; 21(6):4418-29.

PMID: 24327113 DOI: 10.1007/s11356-013-2339-9.

Proteomic CNS profile of delayed cognitive impairment in mice exposed to Gulf War agents.

Abdullah L, Crynen G, Reed J, Bishop A, Phillips J, Ferguson S Neuromolecular Med. 2011; 13(4):275-88.

PMID: 21986894 DOI: 10.1007/s12017-011-8160-z.

Treatment of myasthenia gravis: focus on pyridostigmine.

Maggi L, Mantegazza R Clin Drug Investig. 2011; 31(10):691-701.

PMID: 21815707 DOI: 10.2165/11593300-000000000-00000.

Diagnosis and management of autoimmune myasthenia gravis.

Angelini C Clin Drug Investig. 2010; 31(1):1-14.

PMID: 21053987 DOI: 10.2165/11584740-000000000-00000.

References

KORNFELD P, SAMUELS A, Wolf R, OSSERMAN K . Metabolism of 14C-labeled pyridostigmine in myasthenia gravis. Evidence for multiple metabolites. Neurology. 1970; 20(7):634-41. DOI: 10.1212/wnl.20.7.634. View

OOSTERHUIS H . STUDIES IN MYASTHENIA GRAVIS. 1. A CLINICAL STUDY OF 180 PATIENTS. J Neurol Sci. 1964; 1(6):512-46. DOI: 10.1016/0022-510x(64)90171-6. View

Cohan S, Pohlmann J, Mikszewski J, ODOHERTY D . The pharmacokinetics of pyridostigmine. Neurology. 1976; 26(6 PT 1):536-9. DOI: 10.1212/wnl.26.6.536. View

Stalberg E, Trontelj J, SCHWARTZ M . Single-muscle-fiber recording of the jitter phenomenon in patients with myasthenia gravis and in members of their families. Ann N Y Acad Sci. 1976; 274:189-202. DOI: 10.1111/j.1749-6632.1976.tb47685.x. View

Calvey T, Chan K . Plasma pyridostigmine levels in patients with myasthenia gravis. Clin Pharmacol Ther. 1977; 21(2):187-93. DOI: 10.1002/cpt1977212187. View

Chan K, Calvey T . Plasma concentration of pyridostigmine and effects in myastenia gravis. Clin Pharmacol Ther. 1977; 22(5 Pt 1):596-601. DOI: 10.1002/cpt1977225part1596. View

Chan K, Calvey T . Renal clearance of pyridostigmine in patients with myasthenia gravis. Eur Neurol. 1977; 16(1-6):69-72. DOI: 10.1159/000114882. View

Williams N, Calvey T, Chan K . Clearance of neostigmine from the circulation during the antagonism of neuromuscular block. Br J Anaesth. 1978; 50(10):1065-7. DOI: 10.1093/bja/50.10.1065. View

Brown R, Manno J . ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci. 1978; 67(12):1687-91. DOI: 10.1002/jps.2600671214. View

10.

Aquilonius S, Eckernas S, Hartvig P, Hultman J, Lindstrom B, OSTERMAN P . A pharmacokinetic study of neostigmine in man using gas chromatography-mass spectrometry. Eur J Clin Pharmacol. 1979; 15(5):367-71. DOI: 10.1007/BF00558442. View

11.

Cronnelly R, Stanski D, Miller R, Sheiner L . Pyridostigmine kinetics with and without renal function. Clin Pharmacol Ther. 1980; 28(1):78-81. DOI: 10.1038/clpt.1980.134. View

12.

Aquilonius S, Eckernas S, Hartvig P, Lindstrom B, OSTERMAN P . Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur J Clin Pharmacol. 1980; 18(5):423-8. DOI: 10.1007/BF00636797. View

13.

White M, Silva P, Havard C . Plasma pyridostigmine levels in myasthenia gravis. Neurology. 1981; 31(2):145-50. DOI: 10.1212/wnl.31.2.145. View

14.

Chan K, Davison S, Dehghan A, Hyman N . The effect of neostigmine on pyridostigmine bioavailability in myasthenic patients after oral administration. Methods Find Exp Clin Pharmacol. 1981; 3(5):291-6. View

15.

Davison S, Hyman N, Dehghan A, Chan K . The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry. 1981; 44(12):1141-5. PMC: 491235. DOI: 10.1136/jnnp.44.12.1141. View

16.

Chan K, Williams N, Baty J, Calvey T . A quantitative gas-liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasma. J Chromatogr. 1976; 120(2):349-58. DOI: 10.1016/s0021-9673(76)80012-x. View